Drug Approval | May 07, 2026
Venus Remedies gets marketing authorization for Ceftriaxone in Argentina
Approval strengthens the company’s growing international anti-infective portfolio
Approval strengthens the company’s growing international anti-infective portfolio
The US regulator conducted an inspection at the Amaliya manufacturing plant between April 20 and May 1, 2026
Company confirms seized products were not from its authorised supply chain and urges patients to purchase medicines only through licensed pharmacies
The company said it is supporting the ongoing investigation and reiterated its commitment to patient safety.
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
Venglustat, a glucosylceramide synthase inhibitor (GCSi), works by reducing the abnormal buildup of sugar-and-fat molecules in cells and organs
WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation
Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
Subscribe To Our Newsletter & Stay Updated
